NRX Pharmaceuticals, Inc. — fact timeline

NRX Pharmaceuticals, Inc. entered into Underwriting Agreement with BTIG, LLC valued at approximately $18.8 million (or $21.6 million, if the Underwriters’ option to purchase additional sh (effective 2026-06-03).

“On June 3, 2026, NRx Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with BTIG, LLC, as representative of the several underwriters listed in Schedule A thereto (the “ Underwriters ”) in connection with a public offering of an aggregate of 5,714,286 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), by the Company at a price to the public of $3.50 per share (the “ Offering ”).”

NRX Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding other (rules 5810(b)).

“assurance that Nasdaq will accept the Company’s plan or that the Company will be able to regain compliance within any extension period granted by Nasdaq or maintain compliance with the other continued listing requirements set forth in the Nasdaq Listing Rules. In accordance with Nasdaq Listing Rule 5810(b), the Company is required to disclose the receipt of the Nasdaq Letter. The Nasdaq Letter has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq, which will continue to trade under the symbol “NRXP.” However, beginning five business days from the date of the”

NRX Pharmaceuticals, Inc. engaged Weinberg & Company P.A. as its auditor.

“Engagement of New Independent Registered Public Accounting Firm and Dismissal of Independent Registered Public Accounting Firm On November 20, 2025, the audit committee of the board of directors (the “Audit Committee”) of NRx Pharmaceuticals, Inc. (the “Corporation”) approved the engagement of Weinberg & Company P.A. (“Weinberg”) as the Corporation’s independent registered public accounting firm for the fiscal year ending December 31, 2025. Weinberg had been previously engaged to audit the financial statements of Dura Medical LLC, which had been acquired by Hope Therapeutics, Inc.”

NRX Pharmaceuticals, Inc. dismissed Salberg & Company P.A. as its auditor.

“on or around November 24, 2025 the Audit Committee of the Corporation dismissed Salberg & Company P.A.”

NRX Pharmaceuticals, Inc. completed an acquisition involving Dura Medical, LLC for a combination of cash, membership interests in HTX Management Company LLC (which are convertible into shares of Hope Therapeutics on a one-for-one basis at the (closed 2025-09-08).

“On September 8, 2025, NRx Pharmaceuticals (NASDAQ: NRXP, or the “Company”), principally through its subsidiary HOPE Therapeutics, Inc., a Delaware corporation, completed its previously announced acquisition of Dura Medical, LLC”

Mike Taylor was appointed as Director at NRX Pharmaceuticals, Inc..

“On January 15, 2025, NRx Pharmaceuticals, Inc. (the “ Company ”) appointed Mike Taylor as a Class I member of the Board of Directors of the Company (“ Board ”).”

Janet Rehnquist resigned as Director at NRX Pharmaceuticals, Inc..

“Mr. Taylor was appointed to fill the seat vacated as a result of the resignation from the Board of Janet Rehnquist on January 7, 2025.”

Janet Rehnquist resigned as member of the Board of Directors at NRX Pharmaceuticals, Inc..

“On January 7, 2025, Janet Rehnquist resigned as a member of the Board of Directors (“ Board ”) of NRx Pharmaceuticals, Inc. (the “ Company ”), effective immediately.”

Richard Narido changed role as Interim Chief Financial Officer at NRX Pharmaceuticals, Inc..

“Mr. Abrams succeeds Interim Chief Financial Officer Richard Narido, who will continue to support the Company’s financial function and other projects.”

Michael Abrams was appointed as Chief Financial Officer at NRX Pharmaceuticals, Inc..

“On November 18, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the appointment of Michael Abrams as the Chief Financial Officer of the Company.”

Jonathan Javitt was appointed as Interim Chief Executive Officer at NRX Pharmaceuticals, Inc..

“Jonathan Javitt, Chairman of the Board of Directors of the Company, was appointed as Interim Chief Executive Officer concurrent with Mr. Willard’s resignation.”

Stephen Willard resigned as Chief Executive Officer at NRX Pharmaceuticals, Inc..

“On October 7, 2024, Stephen Willard, the Chief Executive Officer of NRx Pharmaceuticals, Inc. (the “ Company ”) provided notice to the Board that he was resigning from the Company, effective immediately”

Dr. Dennis McBride was appointed as member of the Board of Directors at NRX Pharmaceuticals, Inc..

“On June 13, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) appointed Dr. Dennis McBride to serve as a member of the Board of Directors of the Company.”

NRX Pharmaceuticals, Inc. reported financial results for quarter ended March 31, 2024.

“NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter ended March 31, 2024, and provided a business update.”

NRX Pharmaceuticals, Inc. reported financial results for first quarter ending March 31, 2024.

“On May 14, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ending March 31, 2024”

NRX Pharmaceuticals, Inc. faced acceleration on convertible notes of $11,020,000.00 with Streeterville Capital, LLC.

“Note (the "Note") dated November 4, 2022 issued by NRX Pharmaceuticals, Inc., a Delaware corporation ("Borrower"), in favor of Lender, in the original principal amount of $11,020,000.00, as amended by that certain Amendment to Convertible Promissory Note dated March 30, 2023 ("Amendment #1"), that certain Amendment #2 to Convertible Promissory Note dated July”

NRX Pharmaceuticals, Inc. entered into Underwriting Agreement with EF Hutton LLC valued at approximately $2.0 million (effective 2024-04-18).

“On April 18, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with EF Hutton LLC (the “ Representative ”), as the representative of the several underwriters named therein (the “ Underwriters ”), relating to an underwritten public offering (the “ Offering ”) of 607,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (“ Common Stock ”).”

NRX Pharmaceuticals, Inc. reported financial results for the fourth fiscal quarter and year ending December 31, 2023.

“On April 1, 2024, NRx Pharmaceuticals, Inc. issued a press release announcing its financial results for the fourth fiscal quarter and year ending December 31, 2023 and provided a business update.”

NRX Pharmaceuticals, Inc.: Amendment to certificate of incorporation to effect a 1-for-10 reverse stock split of common stock, effective April 1, 2024 (effective 2024-04-01).

“On March 28, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) announced that it had filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “ Charter Amendment ”) to effect a 1-for-10 reverse stock split (the “ Reverse Stock Split ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), effective as of 4:30 p.m. Eastern Standard Time on April 1, 2024 (the “ Effective Time ”).”

NRX Pharmaceuticals, Inc. shareholders approved Reverse stock split of all outstanding shares at a ratio in the range of 1-for-2 to 1-for-15 at the 2024-03-21 meeting.

“Proposal 1. The Company’s stockholders approved an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to effect, at the discretion of the Board of Directors of the Company (the “Board”) but prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Special Meeting, a reverse stock split of all of the outstanding shares of the Company’s common stock, $0.001 par value per share, at a ratio in the range of 1-for-2 to 1-for-15, with such ratio to be determined by the Board in its discretion and included in a public announcement.”

NRX Pharmaceuticals, Inc. entered into Underwriting Agreement with EF Hutton LLC (effective 2024-02-27).

“On February 27, 2024, NRx Pharmaceuticals, Inc. (the " Company ") entered into an underwriting agreement (the " Underwriting Agreement ") with EF Hutton LLC (the " Representative "), as the representative of the several underwriters named therein (the " Underwriters "), relating to an underwritten public offering (the " Offering ") of 5,000,000 shares (the " Shares ") of the Company’s common stock, par value $0.001 per share (" Common Stock ").”

NRX Pharmaceuticals, Inc. amended First Amendment with Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. valued at $5 million (effective 2024-02-07).

“On February 7, 2024, NeuroRx, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (together, the “ Company ”), entered into the First Amendment (the “ Amendment ”) to the Exclusive, Global Development, Supply, Marketing & License Agreement, dated as of June 2, 2023 (the “ License Agreement ”), with Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (collectively, “ Alvogen ”), effective as of the same date.”

NRX Pharmaceuticals, Inc. amended Amendment #3 to Convertible Promissory Note with Streeterville Capital, LLC valued at $1,100,000 (effective 2024-02-09).

“On February 9, 2024 NRX Pharmaceuticals, Inc. (the “Company”) entered into Amendment #3 to Convertible Promissory Note (the “Third Amendment”), with Streeterville Capital, LLC (“Streeterville”).”

NRX Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).

“February 1, 2024, Nasdaq informed the Company that it had approved the Company’s application to transfer its listing and that the Company’s securities were transferred to The Nasdaq Capital Market at the opening of business on January 19, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: February 2, 2024 By: /s/ Stephen Willard Name: Stephen Willard Title: Acting General Counsel”

NRX Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5550(a)(2)).

“October 17, 2023, NRx Pharmaceuticals, Inc. (the “Company”) received formal notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s non-compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Rule”), the Company’s securities were subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company timely requested a hearing before the Panel, which hearing”

NRX Pharmaceuticals, Inc. shareholders approved Advisory vote on frequency of future advisory votes on executive compensation.

“The Company’s stockholders approved, on an advisory basis, the frequency of holding an advisory vote on executive compensation.”

NRX Pharmaceuticals, Inc. shareholders approved Advisory vote on compensation of named executive officers.

“The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as set forth in the Proxy Statement.”

NRX Pharmaceuticals, Inc. shareholders approved Ratification of Salberg & Company, P.A. as independent auditors for fiscal year 2023 at the 2023-12-31 meeting.

“The Company’s stockholders ratified the selection of Salberg & Company, P.A. as the Company’s independent auditors for the fiscal year ending December 31, 2023.”

NRX Pharmaceuticals, Inc. shareholders approved Approval of the Plan Amendment.

“The Company’s stockholders approved the Plan Amendment.”

NRX Pharmaceuticals, Inc. shareholders approved Election of Janet Rehnquist as a Class II director.

“The Company’s stockholders duly elected Janet Rehnquist to serve as a Class II member of the Company’s board of directors until the 2026 Annual Meeting or until the appointment, election, and qualification of her successor.”

NRX Pharmaceuticals, Inc. engaged Salberg & Company, P.A. as its auditor.

“On November 17, 2023, the Board engaged Salberg & Company, P.A. (“Salberg”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, effective immediately.”

NRX Pharmaceuticals, Inc. dismissed KPMG LLP as its auditor.

“On November 15, 2023, the Board of Directors (the “Board”) of the Company approved the dismissal of KPMG as the Company’s independent registered public accounting firm, effective immediately.”

NRX Pharmaceuticals, Inc. engaged Salberg & Company, P.A. as its auditor.

“On November 17, 2023, the Board engaged Salberg & Company, P.A. (“Salberg”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, effective immediately.”

NRX Pharmaceuticals, Inc. dismissed KPMG LLP as its auditor.

“On November 15, 2023, the Board of Directors (the “Board”) of NRx Pharmaceuticals, Inc. (the “Company”) approved the dismissal of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm, effective immediately.”

NRX Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2023.

“On November 13, 2023, NRx Pharmaceuticals, Inc. issued a press release announcing its financial results for the third fiscal quarter ending September 30, 2023 and provided a business update.”

NRX Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“October 17, 2023, NRx Pharmaceuticals, Inc. (the “Company”) received formal notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s non-compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”), the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which”

Richard Narido was appointed as Interim Chief Financial Officer at NRX Pharmaceuticals, Inc..

“on September 13, 2023, the Company appointed Richard Narido, 45, to serve as Interim Chief Financial Officer of the Company.”

Seth Van Voorhees resigned as Chief Financial Officer at NRX Pharmaceuticals, Inc..

“On September 11, 2023, Seth Van Voorhees, Ph.D., resigned from his position as the Chief Financial Officer of the Company. His resignation will be effective as of September 30, 2023, in order to facilitate a smooth transition.”

NRX Pharmaceuticals, Inc.: Filed Certificate of Designation for Series A Convertible Preferred Stock, establishing preferences, rights, and limitations (effective 2023-08-30).

“On August 30, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock with the Delaware Secretary of State (the "Certificate of Designation") authorizing up to 12,000,000 shares of Series A Convertible Preferred Stock.”

NRX Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the purchasers signatory thereto (the "Investors") valued at approximately $1.2 million (effective 2023-08-28).

“On August 28, 2023, the Company entered into a securities purchase agreement (the "Securities Purchase Agreement") with the purchasers signatory thereto (the "Investors"), pursuant to which the Company issued 3,000,000 shares of the Company’s Series A Convertible Preferred Stock, par value $0.001 per share (the " Series A Preferred Stock "), and one (1) investor warrant (each an "Investor Warrant") for every share of Series A Convertible Preferred Stock issued.”

NRX Pharmaceuticals, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to $2,000,000 (effective 2023-08-14).

“On August 14, 2023, NRX Pharmaceuticals, Inc. (the “Company”), entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent, pursuant to which the Company may offer and sell, from time to time through Wainwright, shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $2,000,000 (the “Shares”).”

NRX Pharmaceuticals, Inc. amended Amendment #2 to Convertible Promissory Note with Streeterville Capital, LLC (effective 2023-07-07).

“On July 7, 2023, NRX Pharmaceuticals, Inc. (the “Company”) entered into Amendment #2 to Convertible Promissory Note (the “Second Amendment”), with Streeterville Capital, LLC (the “Streeterville”).”

NRX Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“July 20, 2023, the Company received a written notification (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(b)(2)(A) – Market Value of Listed Securities (“MVLS”) because the Company has not maintained a minimum MVLS of $50,000,000 for the last thirty-three (33) consecutive business days. Nasdaq’s Notice has no immediate effect on the listing of the common stock on The Nasdaq Global Market and, at this time, the common stock will continue to trade on The Nasdaq Global Market under the symbol “NRXP”. Pursua”

NRX Pharmaceuticals, Inc. entered into Engagement Letter with H.C. Wainwright & Co. LLC valued at 6.5% of the gross proceeds (effective 2023-06-03).

“H.C. Wainwright & Co. LLC is acting as the exclusive placement agent (the “Placement Agent”) for the Offering, pursuant to a letter agreement dated June 3, 2023 (the “Engagement Letter”).”

NRX Pharmaceuticals, Inc. entered into Lock-Up Agreement with Jonathan Javitt, Daniel Javitt, and entities controlled by them.

“Jonathan Javitt, Director and Chief Scientist, and Daniel Javitt, the brother of Jonathan Javitt, and entities controlled by them, have entered into a customary lock-up agreement (the “Lock-Up Agreement”) with the Company providing that each will not transfer shares of Common Stock and certain other securities held by them for a period of 60 days following the closing of the Offering.”

NRX Pharmaceuticals, Inc. amended Warrant Amendment Agreement with certain Investors.

“the Company also entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with certain Investors to amend certain existing warrants to purchase up to 9,622,778 shares of Common Stock”

NRX Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the purchasers signatory thereto (the 'Investors') valued at approximately $6.28 million (effective 2023-06-06).

“On June 6, 2023, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with the purchasers signatory thereto (the “Investors”), providing for the issuance and sale of 9,670,002 shares of the Company’s common stock (“Common Stock”) and warrants to purchase up to 9,670,002 shares of Common Stock (the “Investor Warrants”) (or pre-funded warrants in lieu thereof).”

NRX Pharmaceuticals, Inc. entered into Engagement Letter with H.C. Wainwright & Co. LLC (effective 2023-06-03).

“H.C. Wainwright & Co. LLC is acting as the exclusive placement agent (the “Placement Agent”) for the Offering, pursuant to a letter agreement dated June 3, 2023 (the “Engagement Letter”).”

NRX Pharmaceuticals, Inc. entered into Lock-Up Agreement with Jonathan Javitt and Daniel Javitt and entities controlled by them.

“Jonathan Javitt, Director and Chief Scientist, and Daniel Javitt, the brother of Jonathan Javitt, and entities controlled by them, have entered into a customary lock-up agreement (the “Lock-Up Agreement”) with the Company providing that each will not transfer shares of Common Stock and certain other securities held by them for a period of 60 days following the closing of the Offering.”

NRX Pharmaceuticals, Inc. amended Warrant Amendment Agreement with certain Investors (effective 2023-06-06).

“the Company also entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with certain Investors to amend certain existing warrants to purchase up to 9,622,778 shares of Common Stock that were previously issued in August 2021 and February 2022 to the Investors”